Global Neurostimulation Devices Market to grow at a CAGR of 11.77% by 2030, Evaluates DelveInsight | Abbott Laboratories, Smith's Medical, B. Braun Melsungen AG, Baxter International Inc., Boston Scientific Corp., LivaNova PLC., Medtronic plc., Nevro Corp

According to DelveInsight's analysis, The neurostimulator devices market is witnessing substantial growth, driven by several major factors. A growing number of chronic conditions-such as migraines, epilepsy, and headaches-has led to increased demand for effective treatment options, encouraging the adoption of neurostimulators. Additionally, the rise in lifestyle-related disorders like depression and chronic pain has further fueled demand for these devices due to their effectiveness in managing such conditions. Technological innovations in neurostimulation have also significantly contributed to market expansion, with global regulatory agencies increasingly approving advanced and novel devices. This regulatory backing has supported broader usage, propelling overall market growth.

DelveInsight's "Neurostimulation Devices Market Insights, Competitive Landscape and Market Forecast-2030" report provides the current and forecast market outlook, forthcoming device innovation, challenges, market drivers and barriers. The report also covers the major emerging products and key Neurostimulation Devices companies actively working in the market.

To know more about why North America is leading the market growth in the Neurostimulation Devices market, get a snapshot of the report Neurostimulation Devices Market Trends
https://www.delveinsight.com/sample-request/neurostimulation-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Neurostimulation Devices Overview
Neurostimulation devices are medical devices that deliver mild electrical impulses to specific parts of the nervous system to modulate nerve activity. These devices are used to treat a variety of neurological and chronic conditions, including chronic pain, epilepsy, Parkinson's disease, depression, and spinal cord injuries.

DelveInsight Analysis: The neurostimulation devices market was estimated at USD 5.82 billion in 2023 and is projected to expand at a compound annual growth rate (CAGR) of 11.77% from 2024 to 2030, reaching approximately USD 11.34 billion by the end of the forecast period.

Neurostimulation Devices Market Insights
Geographically, North America is projected to hold the largest share of the neurostimulation devices market in 2023 and is expected to continue leading throughout the forecast period. The rising incidence of chronic pain in the region is likely to drive demand for neurostimulation devices. Furthermore, recent product approvals and launches by companies specializing in pain management devices will support market expansion. In addition, growing government initiatives aimed at raising awareness and promoting related healthcare programs are expected to further accelerate market growth across the region.

To read more about the latest highlights related to Neurostimulation Devices, get a snapshot of the key highlights entailed in the Neurostimulation Devices
https://www.delveinsight.com/report-store/neurostimulation-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Recent Developments in the Neurostimulation Devices Market Report
• In May 2023, Abbott announced that the FDA has approved its spinal cord stimulation (SCS) devices for the treatment of chronic back pain in patients who are not candidates for back surgery, referred to as non-surgical back pain. This expanded indication is based on findings from the DISTINCT study, which demonstrated that Abbott's BurstDRTM SCS technology effectively reduced pain, enhanced daily functioning, and improved emotional well-being in individuals with chronic back pain.
• In March 2023, Nevro Corp. announced the nationwide U.S. launch of its HFX iQ spinal cord stimulation (SCS) system, following a successful initial limited release.
• In October 2022, Nevro Corp., a global medical device leader specializing in innovative chronic pain management solutions, announced it has received U.S. Food and Drug Administration (FDA) approval for its Senza HFX iQ spinal cord stimulation (SCS) system.
• In August 2022, Merck announced a partnership in its emerging Bioelectronics innovation area with neuroloop GmbH, a subsidiary of B. Braun, to develop a neurostimulator device designed to support and enhance current drug treatments for patients with chronic inflammatory conditions.
• In July 2022, Unity HA has been granted Breakthrough Device Designation by the FDA for its Pulsante® SPG Microstimulator System, intended for treating acute pain linked to chronic cluster headaches.
• Thus, owing to such developments in the market, rapid growth will be observed in the Neurostimulation Devices market during the forecast period

Key Players in the Neurostimulation Devices Market
Some of the key market players operating in the Neurostimulation Devices market include- Abbott Laboratories, Smith's Medical, B. Braun Melsungen AG, Baxter International Inc., Boston Scientific Corp., LivaNova PLC., Medtronic plc., Nevro Corp., Abbott, Stryker, Omron Corporation, Stimwave LLC, Koninklijke Philips NV, Kimberly Clark Corporation, EndoStim Inc., Aleva neurotherapeutics SA, Cyberonics, DyAnsys, Inc., NanoVibronix, Inc., ElectroCore Inc., and others.

Which MedTech key players in the Neurostimulation Devices market are set to emerge as the trendsetter explore @ Key Neurostimulation Devices Companies
https://www.delveinsight.com/sample-request/neurostimulation-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Analysis on the Neurostimulation Devices Market Landscape
According to recent data from the World Health Organization (2024), epilepsy impacts around 50 million individuals globally, ranking it among the most common neurological disorders. Approximately 80% of these individuals live in low- and middle-income countries. Neurostimulation devices, such as vagus nerve stimulators and responsive neurostimulators, present effective options for managing epilepsy by decreasing the frequency and intensity of seizures. This, in turn, is contributing to the global expansion of the neurostimulation devices market.
The approval of various spinal cord stimulators for chronic pain management is expected to significantly drive segment growth. For example, in August 2023, Medtronic plc, a global healthcare technology leader, received CE mark approval for its InceptivTM closed-loop rechargeable spinal cord stimulator (SCS). This was Medtronic's first SCS device featuring closed-loop technology, which detects an individual's unique biological signals and continuously adjusts stimulation to align with their movements throughout the day. As a result of such developments, the spinal cord stimulator segment is anticipated to generate substantial revenue, contributing to the overall expansion of the global neurostimulation devices market during the forecast period.

Scope of the Neurostimulation Devices Market Report
• Coverage: Global
• Study Period: 2021-2030
• Neurostimulation Devices Market Segmentation By Type: (Spinal Cord Stimulators, Deep Brain Stimulators, Sacral Nerve Stimulators, Vagus Nerve Stimulators, and Others
• Neurostimulation Devices Market Segmentation By Application Type: Pain Management, Bowel & Bladder Control, Parkinson's Disease, Epilepsy, and Others
• Neurostimulation Devices Market Segmentation By End-User: Hospitals, Ambulatory Surgical Centers, and Others
• Neurostimulation Devices Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of the World
• Key Neurostimulation Devices Companies: Abbott Laboratories, Smith's Medical, B. Braun Melsungen AG, Baxter International Inc., Boston Scientific Corp., LivaNova PLC., Medtronic plc., Nevro Corp., Abbott, Stryker, Omron Corporation, Stimwave LLC, Koninklijke Philips NV, Kimberly Clark Corporation, EndoStim Inc., Aleva neurotherapeutics SA, Cyberonics, DyAnsys, Inc., NanoVibronix, Inc., ElectroCore Inc., and others
• Porter's Five Forces Analysis, Product Profiles, Case Studies, KOL's Views, Analyst's View

Interested in knowing how the Neurostimulation Devices market will grow by 2030? Click to get a snapshot of the Neurostimulation Devices Market Analysis
https://www.delveinsight.com/sample-request/neurostimulation-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1 Neurostimulation Devices Market Report Introduction
2 Neurostimulation Devices Market Executive summary
3 Regulatory and Patent Analysis
4 Neurostimulation Devices Market Key Factors Analysis
5 Porter's Five Forces Analysis
6 COVID-19 Impact Analysis on Neurostimulation Devices Market
7 Neurostimulation Devices Market Layout
8 Global Company Share Analysis - Key 3-5 Companies
9 Company and Product Profiles
10 Project Approach
11 Neurostimulation Devices Market Drivers
12 Neurostimulation Devices Market Barriers
13 About DelveInsight

Latest Reports by DelveInsight
• Tbi Market: https://www.delveinsight.com/report-store/traumatic-brain-injury-market
• Indwelling Catheters Market: https://www.delveinsight.com/report-store/indwelling-catheters-market
• Hyperlipidemia Market: https://www.delveinsight.com/report-store/hyperlipidemia-market
• Inflammatory Bowel Disease Market: https://www.delveinsight.com/report-store/crohns-disease-cd-market
• Post Menopausal Osteoporosis Market: https://www.delveinsight.com/report-store/post-menopausal-osteoporosis-pipeline-insight
• HiPost Menopausal Osteoporosis Market: https://www.delveinsight.com/report-store/post-menopausal-osteoporosis-pipeline-insight
• Hip Replacement Devices Market: https://www.delveinsight.com/report-store/hip-reconstruction-devices-market

Contact Us
Gaurav Bora
info@delveinsight.com
+14699457679
www.delveinsight.com

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.